IAS 2023

Biktarvy Continues to Show Safety and Efficacy Across Diverse Populations Impacted by the Global HIV Epidemic: Updated Findings from IAS 2023

Source – Gilead Gilead Sciences, has released the results of several studies further solidifying Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir ...